Alpharadin radium-223: Phase I/IIa started

Algeta began an open-label, U.S. Phase I/IIa trial to evaluate docetaxel plus IV Alpharadin for up to five 6-week cycles in 60 patients. The first part will combine docetaxel every 3 weeks with escala...